RemeGen (9995 HK)

311

Analysis

Health Care • China

RemeGen is a China-based biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, for major diseases such as autoimmune disorders, oncology, and ophthalmology. Key products include Telitacicept (RC18) and Disitamab Vedotin (RC48). RemeGen was co-founded in 2008 and is headquartered in Yantai, Shandong Province, China.

Refresh

Exchange Announcement • 14 Oct 2026 17:26

Discloseable Transaction - Purchase Of Wealth Management Products

Exchange Announcement • 28 Sep 2026 16:36

Resignation Of Joint Company Secretary And Change Of Authorised Representative

Exchange Announcement • 23 Sep 2026 16:30

2026 Interim Report

Exchange Announcement • 11 Sep 2026 17:05

Next Day Disclosure Return

Exchange Announcement • 02 Sep 2026 19:08

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Discloseable Transaction - Purchase Of Wealth Management Products

Resignation Of Joint Company Secretary And Change Of Authorised Representative

2026 Interim Report

Next Day Disclosure Return

Disclosable Transaction - Purchase Of Wealth Management Products